Carbamazepine Capsule, Extended Release shortage
To Be Discontinued 3 presentations · 1 manufacturers · first FDA posting 2025-12-19 · last update 2025-12-19
Manufacturers: Takeda Pharmaceuticals USA Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12) | Takeda Pharmaceuticals USA Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 12/19/2025 Updated 12/19/2025 Discontinued 12/19/2025 |
| Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12) | Takeda Pharmaceuticals USA Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 12/19/2025 Updated 12/19/2025 Discontinued 12/19/2025 |
| Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12) | Takeda Pharmaceuticals USA Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 12/19/2025 Updated 12/19/2025 Discontinued 12/19/2025 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)